

J Michael Kilby

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8723225/j-michael-kilby-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49
papers

8,199
citations

27
h-index

90
g-index

155
ext. papers

8,891
ext. citations

12.1
avg, IF

4.7
L-index

#	Paper	IF	Citations
49	Antibody neutralization and escape by HIV-1. <i>Nature</i> , 2003 , 422, 307-12	50.4	1978
48	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 7552-7	11.5	1472
47	Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 1896-905	5.9	1310
46	Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. <i>Nature Medicine</i> , 1998 , 4, 1302-7	50.5	900
45	Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. <i>Journal of Clinical Investigation</i> , 1999 , 103, 1391-8	15.9	255
44	Novel therapies based on mechanisms of HIV-1 cell entry. <i>New England Journal of Medicine</i> , 2003 , 348, 2228-38	59.2	208
43	SIVcpz in wild chimpanzees. <i>Science</i> , 2002 , 295, 465	33.3	181
42	Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. <i>Journal of Experimental Medicine</i> , 1999 , 189, 1545-54	16.6	178
41	The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. <i>AIDS Research and Human Retroviruses</i> , 2002 , 18, 685-93	1.6	170
40	A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. <i>Journal of Infectious Diseases</i> , 2006 , 194, 725-33	7	141
39	Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. <i>Journal of Infectious Diseases</i> , 2011 , 203, 442-51	7	132
38	Modeling sequence evolution in acute HIV-1 infection. <i>Journal of Theoretical Biology</i> , 2009 , 261, 341-60	2.3	128
37	Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 4512-7	11.5	119
36	Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. <i>Journal of Infectious Diseases</i> , 2004 , 189, 1075-83	7	116
35	A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. <i>Aids</i> , 2003 , 17, 691-8	3.5	104
34	Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 2672-8	5.9	83
33	A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). <i>Journal of Infectious Diseases</i> , 2006 , 194, 1672-6	7	72

32	Gender differences in discontinuation of antiretroviral treatment regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 52, 336-41	3.1	62
31	Factors associated with delayed initiation of HIV medical care among infected persons attending a southern HIV/AIDS clinic. <i>Southern Medical Journal</i> , 2006 , 99, 472-81	0.6	54
30	Delayed access to HIV diagnosis and care: Special concerns for the Southern United States. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2006 , 18 Suppl 1, S35-44	2.2	50
29	Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report. <i>Annals of Internal Medicine</i> , 2000 , 133, 435-8	8	48
28	CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides. <i>Aids</i> , 2005 , 19, 241-50	3.5	41
27	Enfuvirtide. <i>Expert Opinion on Investigational Drugs</i> , 2002 , 11, 1837-43	5.9	31
26	Correlation between circulating stromal cell-derived factor 1 levels and CD4+ cell count in human immunodeficiency virus type 1-infected individuals. <i>AIDS Research and Human Retroviruses</i> , 1999 , 15, 1063-71	1.6	31
25	The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. <i>Journal of Infectious Diseases</i> , 2010 , 201, 1298-302	7	27
24	The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. <i>Archives of Internal Medicine</i> , 2007 , 167, 597-605		27
23	Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. <i>Aids</i> , 2008 , 22, 957-62	3.5	22
22	Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 240-7	1.6	20
21	Functionally competent antigen-specific CD127(hi) memory CD8+ T cells are preserved only in HIV-infected individuals receiving early treatment. <i>Journal of Infectious Diseases</i> , 2007 , 195, 108-17	7	20
20	Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients. <i>Journal of Clinical Virology</i> , 2004 , 30, 183-90	14.5	18
19	Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics?. <i>Aids</i> , 2001 , 15 Suppl 2, S36-42	3.5	18
18	Humoral immune responses to <i>Streptococcus pneumoniae</i> in the setting of HIV-1 infection. <i>Vaccine</i> , 2015 , 33, 4430-6	4.1	16
17	Pathological Role of Anti-CD4 Antibodies in HIV-Infected Immunologic Nonresponders Receiving Virus-Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017 , 216, 82-91	7	13
16	Use of an Outreach Coordinator to Reengage and Retain Patients with HIV in Care. <i>AIDS Patient Care and STDs</i> , 2017 , 31, 222-226	5.8	13
15	Plasmacytoid dendritic cells mediate synergistic effects of HIV and lipopolysaccharide on CD27+ IgD- memory B cell apoptosis. <i>Journal of Virology</i> , 2014 , 88, 11430-41	6.6	13

14	Actinomyces meyeri, a Common Agent of Actinomycosis. <i>American Journal of the Medical Sciences</i> , 2016 , 352, 53-62	2.2	12
13	Key differences in B cell activation patterns and immune correlates among treated HIV-infected patients versus healthy controls following influenza vaccination. <i>Vaccine</i> , 2016 , 34, 1945-55	4.1	12
12	CD8 T-cell proliferative capacity is compromised in primary HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, 213-21	3.1	11
11	Human immunodeficiency virus pathogenesis: insights from studies of lymphoid cells and tissues. <i>Clinical Infectious Diseases</i> , 2001 , 33, 873-84	11.6	11
10	Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 1999 , 8, 1157-70	5.9	10
9	Switching HIV therapies: competing host and viral factors. <i>Lancet, The</i> , 2010 , 375, 352-4	4.0	3
8	The induction of CD80 and apoptosis on B cells and CD40L in CD4+ T cells in response to seasonal influenza vaccination distinguishes responders versus non-responders in healthy controls and aviremic ART-treated HIV-infected individuals. <i>Vaccine</i> , 2017 , 35, 831-841	4.1	2
7	Therapeutic immunization strategies for HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2006 , 1, 74-81	4.2	2
6	Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice. <i>Clinical Infectious Diseases</i> , 2000 , 31, 1095-7	11.6	2
5	Images in clinical medicine. Cytomegalovirus esophageal ulcers. <i>New England Journal of Medicine</i> , 2000 , 342, 475	59.2	
4	Human Immunodeficiency Virus 2001 , 23-43		
3	Salmonella infections in the setting of AIDS: a serpentine course. <i>Southern Medical Journal</i> , 2005 , 98, 1066-7	0.6	
2	Future clinical prospects for entry inhibitors 2007 , 145-160		
1	Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease. <i>Epidemiology (Sunnyvale, Calif)</i> , 2013 , 3, 120	0	